Table 2

Baseline Clinical Characteristics for Patients With RR-NSVT Versus No RR-NSVT

Baseline CharacteristicRR-NSVT (n = 186)No RR-NSVT (n = 625)p Value
Age (yrs)58 (50, 67)61 (53, 70)0.024
Women17% (31)25% (154)0.020
Nonwhite race27% (51)21% (132)0.076
Weight (lb)192 (165, 226)189 (162, 217)0.14
NYHA functional class III35% (66)31% (191)0.21
Ischemic HF etiology40% (74)55% (346)0.001
Ejection fraction (%)20 (18, 26)25 (20, 30)0.001
Diabetes23% (42)33% (205)0.007
Pulmonary disease22% (40)21% (131)0.87
Hyperlipidemia42% (78)55% (343)0.002
Hypertension56% (104)54% (337)0.63
Atrial fibrillation/flutter18% (33)17% (106)0.80
Syncope8% (15)6% (37)0.31
QRS duration ≥120 ms41% (77)41% (259)0.99
Systolic blood pressure (mm Hg)118 (106, 132)118 (104, 130)0.49
Diastolic blood pressure (mm Hg)70 (62, 80)70 (60, 80)0.91
Heart rate (beats/min)76 (68, 88)73 (64, 84)0.008
Serum sodium (mEq/l)139 (137, 141)139 (137, 141)0.52
Serum creatinine (mg/dl)1.10 (0.90, 1.30)1.10 (1.00, 1.40)0.34
ACE inhibitors or ARBs98% (182)93% (584)0.011
Beta-blockers59% (110)73% (455)0.001
Digoxin72% (133)66% (411)0.14
Aspirin51% (95)60% (372)0.041
Statins26% (49)41% (256)0.001
Aldosterone antagonist15% (27)20% (126)0.076

Values are median (25th, 75th percentile) or % (n).

ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker; HF = heart failure; NYHA = New York Heart Association; RR-NSVT = rapid-rate nonsustained ventricular tachycardia.

  • Likelihood ratio chi-square tests for categorical variables and Wilcoxon rank sum tests for continuous variables.